MRD Special Edition: Volume 6 Issue 3

Welcome to the Third 2020 Issue of The CLL Society Tribune focused on MRD

This is the first of several single-issue Tribunes where we can dive deeper into evolving or important topics and recent research findings. Next quarter we will focus on CAR-T therapy, but in this season’s issue we focus our spotlight on MRD, also known as minimal or measurable residual disease. Over the next few years, the role of MRD testing in determining when certain CLL treatments might be safely stopped is expected to become more important. But that is true only in some circumstances and only with some therapies. Patients can prepare by becoming well-informed so as to know when to push for appropriate testing. Please complete our MRD and limited duration survey, and then please read all that we have prepared from patients and experts on this emerging topic, because Smart Patients Get Smart Care™.

Living Well With CLL

My MRD-Negative Journey Meant a New Beginning

By Keith Seagull – Patient

Keith Seagull’s touching memoir of his 16-year CLL survival revealing ardent faith, love of family, and astounding advances in CLL treatment options. … Read more

My Barely Detectable Thoughts on Being Minimal Residual Disease Undetectable

By Stephen Feldman – Patient

Read about Stephen’s experience of having achieved undetectable minimal residual disease status (U-MRD) … Read more

My MRD Journey

By Mark Hoffman – Patient

Watch Mark’s video in which he talks about his clinical trial experience, MRD testing, and how he achieved uMRD. … Read more

MRD Survey

2020 Patient Survey: MRD Testing and Limited Duration Therapy

CLL Society is asking for patient and caregiver participation in a survey which will help us learn about knowledge, attitudes, and preferences about MRD (measurable residual disease or minimal residual disease) and limited duration (also known as fixed duration) therapies. Our goal is to learn more about what our patients know and think so we can best serve you in the future. Please take a few minutes to complete this important survey. … Go to survey!

Subscribe to The CLL Tribune

Learn more about MRD and disease monitoring by visiting our webpage here.

NEW IN 2020!

Submit your stories and questions regarding CAR-T Therapy for our Q4 Special Edition Tribune to support@cllsociety.org!

CLL Tribune is looking for your contribution including articles, storytelling, poems, drawings, or other creative mediums. Please share!

Email support@cllsociety.org with your interest!

MRD Glossary

MRD Testing Glossary

The CLL Society worked with a broad coalition of other stakeholders in the MRD TESTING COLLABORATIVE to produce a glossary of terms for those new to MRD (minimal or measurable residual disease). … Read more

The Basics

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

By Brian Koffman, MDCM

Dr. Koffman breaks down the key takeaways from a recent medical article that describes the MRD landscape. … Read more

Minimal Residual Disease Testing

Be MRD Aware Videos

Two videos featuring our own Dr. Koffman describing the importance of and access to MRD Testing. … Read more

Beyond The Basics

Dr. Susan Leclair on the Mathematics of MRD Testing and More

By Susan Leclair, PhD, CLS (NCA)

Read Dr. Leclair’s two articles that will give you the opportunity to gain helpful insights, not only into understanding your own CLL test results, but also to acquire a good grasp of the current data about COVID-19 results and any other testing data … Read more

Conference Coverage

ASH 2019: Dr. Tam Discusses Captivate Trial – Ibrutinib + Venetoclax in First-Line Treatment

By Thomas. E. Henry III, MBA, RPh, CPh

At ASH 2019 in Orlando, Dr. Brian Koffman interviewed Dr. Constantine Tam about the most recent results of the Captivate Trial – Ibrutinib + Venetoclax in First-Line Treatment. … Watch The Interview

Ask The Doctor: MRD Edition

MRD-specific questions submitted by readers

By Brian Koffman, MDCM (retired), MS, Ed

Dr. Brian Koffman, Chief Medical Officer of the CLL Society, answers readers’ questions submitted to the CLL Society…Read more

Ask The Lab Scientist: MRD Edition

MRD-specific questions submitted by readers

By Susan J. Leclair, PhD, CLS (NCA)

Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society…Read more

Ask The Experts

Questions submitted by readers and answered by our CLL Society experts.

Ask The Doctor

By Richard Furman, MD

Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society…Read more

Ask The Pharmacist

By Thomas E Henry III, MBA, RPh, CPh

Thomas E Henry III, MBA, RPh, CPh from Roswell Park Comprehensive Cancer Center answers readers’ pharmacy questions submitted to the CLL Society…Read more

Ask The Lab Scientist

By Susan J. Leclair, PhD, CLS (NCA)

Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society…Read more

Ask the Hospice/Palliative Care Doctor

By Ed Ratner, MD

Dr. Ratner at the Minneapolis VA Medical Center answers readers’ hospice/palliative care questions submitted to the CLL Society…Read more

The CLL Society Tribune is made possible in part by grant support from AbbVie, Adaptive Biotechnologies, Astra Zeneca, and Genentech.

 

DISCLAIMER
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.